新辅助化疗在晚期透明细胞卵巢癌中的作用:GCIG多机构回顾性队列研究
该多机构回顾性队列研究纳入133例FIGO IIIB-IVB期透明细胞卵巢癌患者,比较新辅助化疗后间隔减瘤术(21例)与初次减瘤术后辅助化疗(112例)的手术结局和生存。两组完全切除率、中位PFS和中位OS均无显著差异,但减瘤至RD≤10 mm与更好OS相关。
要点
- 晚期透明细胞卵巢癌无论治疗方式如何,生存结局均较差。
- 新辅助化疗与初次减瘤术相比,未显著改善可切除性或生存。
- 减瘤至RD≤10 mm与OS改善相关(27.4 vs 10.0个月,p=0.037)。
核心结论
- 在该多机构队列中,晚期透明细胞卵巢癌无论采用新辅助化疗还是初次减瘤术,生存均较差。
- 新辅助化疗与初次减瘤术相比未显著改善可切除性或生存,但最大程度减瘤并达到RD≤10 mm或RD0与更好结局相关,凸显减瘤的预后重要性及开展组织学特异性试验的迫切需求。
研究设计与样本
- 多机构回顾性队列研究,纳入2010年至2024年间在四家三级癌症中心治疗的133例FIGO IIIB-IVB期透明细胞卵巢癌患者。
- 患者接受新辅助化疗后间隔减瘤术(n=21)或初次减瘤术后辅助化疗(n=112)。
- 统计分析包括Wilcoxon秩和检验、卡方/Fisher精确检验、Kaplan-Meier估计和log-rank检验。
主要发现
- 基线特征相似,但新辅助化疗组ECOG体能状态更差(p=0.019)。
- 完全切除(RD0)在新辅助化疗组为48%,在初次减瘤术组为67%(p=0.21)。
- 新辅助化疗组中位PFS为11.0个月,初次减瘤术组为12.4个月(p=0.55);中位OS分别为23.0个月和27.4个月(p=0.15)。
- 减瘤至RD≤10 mm与RD>10 mm相比,OS改善(27.4 vs 10.0个月,p=0.037),但PFS未改善。
- RD0患者相比RD>0患者,OS和PFS在数值上更长,但无统计学显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of neoadjuvant chemotherapy (NACT) versus primary cytoreductive surgery (PCS) on surgical outcomes and survival in in patients with advanced clear cell ovarian cancer (OCCC). METHODS: We conducted a multi-institutional retrospective cohort study of 133 patients with FIGO stage IIIB-IVB OCCC treated between 2010 and 2024 at four tertiary cancer centers. Patients received either NACT followed by interval debulking surgery (n = 21) or PCS followed by adjuvant chemotherapy (n = 112). Statistical analyses included Wilcoxon rank-sum, Chi-square/Fisher's exact test, Kaplan-Meier estimates, and log-rank test. RESULTS: Baseline characteristics were similar, although NACT patients had worse ECOG performance status (p = 0.019). Complete resection (RD0) was achieved in 48 % of NACT patients and 67 % of PCS patients (p = 0.21). Median PFS was 11.0 months with NACT and 12.4 months with PCS (p = 0.55); median OS was 23.0 and 27.4 months, respectively (p = 0.15). Cytoreduction to RD ≤10 mm was associated with improved OS compared with RD >10 mm (27.4 vs 10.0 months, p = 0.037), but not with improved PFS. Patients with RD0 had numerically longer OS and PFS compared to those with RD > 0, though not statistically significant. CONCLUSION: In this multi-institutional cohort, advanced OCCC was associated with poor survival regardless of treatment approach. NACT did not significantly improve resectability or survival compared with PCS. However, maximal surgical effort and achieving RD ≤10 mm or RD0 were associated with better outcomes, underscoring the prognostic importance of cytoreduction and the urgent need for histology-specific trials.
引用
- Somasegar S, Zhang J, Fotopoulou C, et al. The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study. Gynecol Oncol. 2025. PMID: 41004925. doi:10.1016/j.ygyno.2025.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。